Moreover, it was recently shown that erythroblastic predominance without CD41/cyCD41−positive blasts predicts for a favorable prognosis in MDS/AML patients treated with AZA (179) and that emergence of CD41+ blasts, is often accompanied by disease and/or cytogenetic progression (108). This evidence concerns the gene ITGA2B and myelodysplastic syndrome.